中國醫療集團(08225.HK)一季度税前利潤升44.04%至1202.7萬元
格隆匯5月14日丨中國醫療集團(08225.HK)發佈公告,截至2020年3月31日止三個月,集團錄得營業收入人民幣2157.1萬元,較2019年同期營業收入上升31.98%;除税前利潤人民幣1202.7萬元,較2019年同期除税前利潤上升44.04%;每股盈利(基本及攤薄)為人民幣1.06分;不派息。
公告表示,隨着中國醫藥企業商業模式的變化,中國醫療集團承擔起了以CRO以及CSO模式組合替代傳統CSO模式的責任。集團不斷在增強市場推廣能力及拓展市場網路方面做出投資,以中國醫療集團及子品牌喜恩萬全、拜敏萬全、健壽萬全、悦戒煙在本土市場推出全價值鏈的專注治療領域產品品類增值的業務模式;董事會也將按穩建的原則審核評估可能進行的專案或投資,務求提升集團業務表現及公司股東回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.